The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Antibody–drug conjugates: in search of partners of choice
Open accessAbstract
Antibody-drug conjugates (ADCs) have become a credentialled class of anticancer drugs for both solid and hematological malignancies, with regulatory approvals mainly as single agents. Despite extensive preclinical and clinical efforts to develop rational ADC-based combinations, to date only a limited number have demonstrated survival improvements over standard of care. The most appealing partners for ADCs are those that offer additive or synergistic effects on tumor cells or their microenvironment without unacceptable overlapping toxicities. Coadministration with antiangiogenic compounds, HER2-targeting drugs, DNA-damage response agents and immune checkpoint inhibitors (ICIs) represent active forerunners. Through the identification of targets with tumor-specific expression, improved conjugation technologies, and novel linkers and payloads offering superior therapeutic indices, the next generation of ADCs brings optimism to combinatorial approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer
Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., Lin, N. U., Borges, V., Abramson, V., Anders, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914609 · Cited by 1,326
Samanta, D., Park, Y., Ni, X., Li, H., Zahnow, C. A., Gabrielson, E., Pan, F., & Semenza, G. L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718197115 · Cited by 302
Robichaux, J. P., Elamin, Y. Y., Vijayan, R. S. K., Nilsson, M. B., Hu, L., He, J., Zhang, F., Pisegna, M., Poteete, A., Sun, H., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.001 · Cited by 242
Boshuizen, J., Koopman, L. A., Krijgsman, O., Shahrabi, A., van den Heuvel, E. G., Ligtenberg, M. A., Vredevoogd, D. W., Kemper, K., Kuilman, T., Song, J.-Y., et al. (2018) · Nature Medicine · doi:10.1038/nm.4472 · Cited by 229
Research works printed but not linked: 94
- Tarantino, 2022, Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies, CA Cancer J. Clin., 72, 165
- Abrahams, 2019, Abstract NT-090: preclinical activity and safety of STRO-002, a novel ADC targeting folate receptor alpha for ovarian and endometrial cancer, Clin. Cancer Res., 25, 10.1158/1557-3265.OVCASYMP18-NT-090 · doi:10.1158/1557-3265.ovcasymp18-nt-090
- Quanz, 2018, Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models, Oncotarget, 9, 34103, 10.18632/oncotarget.26135 · DOI
- Ponte, 2016, Mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, potentiates the activity of standard of care therapeutics in ovarian cancer models, Neoplasia, 18, 775, 10.1016/j.neo.2016.11.002 · DOI
- Moore, 2018, Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer, Gynecol. Oncol., 151, 46, 10.1016/j.ygyno.2018.07.017 · DOI · Paper page
- O’Malley, 2020, Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer, Gynecol. Oncol., 157, 379, 10.1016/j.ygyno.2020.01.037 · DOI
- Bulat, 2018, Phase Ib study of anti-mesothelin antibody drug conjugate anetumab ravtansine in combination with pegylated liposomal doxorubicin in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer, JCO, 36, 5571, 10.1200/JCO.2018.36.15_suppl.5571 · DOI
- Levy, 2022, MA13.07 TROPION-Lung02: initial results for datopotamab deruxtecan plus pembrolizumab and platinum chemotherapy in advanced NSCLC, J. Thorac. Oncol., 17, S91, 10.1016/j.jtho.2022.07.152 · DOI
- Janjigian, 2022, Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03, JCO, 40, 295, 10.1200/JCO.2022.40.4_suppl.295 · DOI
- Horwitz, 2022, The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma☆, Ann. Oncol., 33, 288, 10.1016/j.annonc.2021.12.002 · doi:10.1016/j.annonc.2021.12.002
- Tilly, 2022, Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma, N. Engl. J. Med., 386, 351, 10.1056/NEJMoa2115304 · DOI · Paper page
- Wahl, 2001, Selective tumor sensitization to taxanes with the mAb-drug conjugate cBR96-doxorubicin, Int. J. Cancer, 93, 590, 10.1002/ijc.1364 · DOI
- Kan, 2015, Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells, BMC Cancer, 15, 726, 10.1186/s12885-015-1772-1 · DOI
- Beck, 2017, Strategies and challenges for the next generation of antibody–drug conjugates, Nat. Rev. Drug Discov., 16, 315, 10.1038/nrd.2016.268 · DOI · Paper page
- Martin, 2016, Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study, Ann. Oncol., 27, 1249, 10.1093/annonc/mdw157 · DOI
- Krop, 2016, Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer, Breast Cancer Res., 18, 34, 10.1186/s13058-016-0691-7 · DOI
- Moore, 2021, Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I, Ann. Oncol., 32, 757, 10.1016/j.annonc.2021.02.017 · DOI · Paper page
- Phillips, 2014, Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy, Clin. Cancer Res., 20, 456, 10.1158/1078-0432.CCR-13-0358 · DOI · Paper page
- Perez, 2017, Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the Phase III MARIANNE Study, J. Clin. Oncol., 35, 141, 10.1200/JCO.2016.67.4887 · DOI · Paper page
- Hurvitz, 2019, Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: three-year outcomes from the Phase III KRISTINE Study, J. Clin. Oncol., 37, 2206, 10.1200/JCO.19.00882 · DOI · Paper page
- Krop, 2022, Trastuzumab emtansine plus pertuzumab versus taxane plus trastuzumab plus pertuzumab after anthracycline for high-risk human epidermal growth factor receptor 2-positive early breast cancer: the phase III KAITLIN Study, J. Clin. Oncol., 40, 438, 10.1200/JCO.21.00896 · DOI
- Lheureux, 2022, A randomized phase II study of bevacizumab and weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or refractory ovarian cancer NCI trial#10150, JCO, 40, 5514, 10.1200/JCO.2022.40.16_suppl.5514 · doi:10.1200/jco.2022.40.16_suppl.5514
- Patel, 2019, A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study), Breast Cancer Res., 21, 100, 10.1186/s13058-019-1186-0 · DOI
- Borges, 2018, Tucatinib combined with ado-trastuzumab emtansine in advanced ERBB2/HER2-positive metastatic breast cancer: a phase 1b clinical trial, JAMA Oncol., 4, 1214, 10.1001/jamaoncol.2018.1812 · DOI · Paper page
- Hurvitz, 2021, 126TiP HER2CLIMB-02: Tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer, Ann. Oncol., 32, S75, 10.1016/j.annonc.2021.03.140 · doi:10.1016/j.annonc.2021.03.140
- Krop, 2021, HER2CLIMB-04: phase 2 open label trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ unresectable locally advanced or metastatic breast cancer with and without brain metastases (trial in progress), JCO, 39, 10.1200/JCO.2021.39.15_suppl.TPS1097 · doi:10.1200/jco.2021.39.15_suppl.tps1097
- Haley, 2021, A phase I/Ib trial of PD 0332991 (palbociclib) and T-DM1 in HER2-positive advanced breast cancer after trastuzumab and taxane therapy, Clin. Breast Cancer, 21, 417, 10.1016/j.clbc.2021.03.005 · DOI
- Spring, 2021, Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer, NPJ Breast Cancer, 7, 103, 10.1038/s41523-021-00311-y · DOI
- Saatci, 2018, Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer, Oncogene, 37, 2251, 10.1038/s41388-017-0108-9 · DOI
- La Monica, 2017, Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines, J. Exp. Clin. Cancer Res., 36, 174, 10.1186/s13046-017-0653-7 · DOI
- Kayatani, 2020, Beneficial effect of erlotinib and trastuzumab emtansine combination in lung tumors harboring EGFR mutations, Biochem. Biophys. Res. Commun., 532, 341, 10.1016/j.bbrc.2020.07.055 · DOI
- Scaltriti, 2009, Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity, Oncogene, 28, 803, 10.1038/onc.2008.432 · DOI · Paper page
- Collins, 2017, Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines, Cell. Immunol., 319, 35, 10.1016/j.cellimm.2017.07.005 · DOI
- O’Brien, 2022, Tucatinib has selective activity in HER2-positive cancers and significant combined activity with approved and novel breast cancer-targeted therapies, Mol. Cancer Ther., 21, 751, 10.1158/1535-7163.MCT-21-0847 · DOI
- Abraham, 2019, Safety and efficacy of T-DM1 plus neratinib in patients with metastatic HER2-positive breast cancer: NSABP Foundation Trial FB-10, J. Clin. Oncol., 37, 2601, 10.1200/JCO.19.00858 · DOI
- Kulukian, 2021, Abstract PS10-08: Tucatinib potentiates the activity of the antibody-drug conjugate T-DM1 in preclinical models of HER2-positive breast cancer, Cancer Res., 81, 10.1158/1538-7445.SABCS20-PS10-08 · doi:10.1158/1538-7445.sabcs20-ps10-08
- Pujade-Lauraine, 2014, Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial, J. Clin. Oncol., 32, 1302, 10.1200/JCO.2013.51.4489 · DOI · Paper page
- Chiorean, 2021, Randomized phase II study of PARP inhibitor ABT-888 (Veliparib) with modified FOLFIRI versus FOLFIRI as second-line treatment of metastatic pancreatic cancer: SWOG S1513, Clin. Cancer Res., 27, 6314, 10.1158/1078-0432.CCR-21-1789 · DOI
- Samol, 2012, Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study, Investig. New Drugs, 30, 1493, 10.1007/s10637-011-9682-9 · DOI · Paper page
- Yap, 2022, Phase Ib SEASTAR Study: combining rucaparib and sacituzumab govitecan in patients with cancer with or without mutations in homologous recombination repair genes, JCO Precis. Oncol., 6
- Cardillo, 2017, Synthetic lethality exploitation by an anti-trop-2-SN-38 antibody-drug conjugate, IMMU-132, plus PARP inhibitors in BRCA1/2-wild-type triple-negative breast cancer, Clin. Cancer Res., 23, 3405, 10.1158/1078-0432.CCR-16-2401 · DOI
- Yap, 2022, CT007 - PETRA: first in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutations, Cancer Res., 82, CT007, 10.1158/1538-7445.AM2022-CT007 · DOI
- Nicolò, 2022, Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives, Cancer Treat. Rev., 106, 10.1016/j.ctrv.2022.102395 · DOI · Paper page
- D’Amico, 2019, A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer, J. Immunother. Cancer, 7, 16, 10.1186/s40425-018-0464-1 · DOI
- Müller, 2014, Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells, Cancer Immunol. Res., 2, 741, 10.1158/2326-6066.CIR-13-0198 · DOI · Paper page
- Iwata, 2018, A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model, Mol. Cancer Ther., 17, 1494, 10.1158/1535-7163.MCT-17-0749 · DOI · Paper page
- Boshuizen, 2021, Cooperative targeting of immunotherapy-resistant melanoma and lung cancer by an AXL-targeting antibody-drug conjugate and immune checkpoint blockade, Cancer Res., 81, 1775, 10.1158/0008-5472.CAN-20-0434 · DOI
- Rios-Doria, 2017, Antibody-drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads are immunomodulatory and synergize with multiple immunotherapies, Cancer Res., 77, 2686, 10.1158/0008-5472.CAN-16-2854 · DOI
- Huang, 2022, A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+tumors in hPD-1 transgenic mouse model and contributes immune memory formation, Breast Cancer Res. Treat., 191, 51, 10.1007/s10549-021-06384-4 · DOI
- Xia, 2021, HER2-targeted antibody-drug conjugate induces host immunity against cancer stem cells, Cell Chem. Biol., 28, 610, 10.1016/j.chembiol.2021.02.013 · doi:10.1016/j.chembiol.2021.02.013
- Emens, 2020, Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial, Lancet Oncol., 21, 1283, 10.1016/S1470-2045(20)30465-4 · DOI · Paper page
- Friedlander, 2021, Study EV-103: update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC), JCO, 39, 4528, 10.1200/JCO.2021.39.15_suppl.4528 · doi:10.1200/jco.2021.39.15_suppl.4528
- Sheng, 2022, JCO, 40, 4518, 10.1200/JCO.2022.40.16_suppl.4518 · doi:10.1200/jco.2022.40.16_suppl.4518
- Galsky, 2022, Primary analysis from DS8201-A-U105: a phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC), JCO, 40, 438, 10.1200/JCO.2022.40.6_suppl.438 · DOI
- Calvo, 2021, Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer, Cancer Treat. Res. Commun., 28
- Malhotra, 2021, A phase 1-2 study of rovalpituzumab tesirine in combination with nivolumab plus or minus ipilimumab in patients with previously treated extensive-stage SCLC, J. Thorac. Oncol., 16, 1559, 10.1016/j.jtho.2021.02.022 · DOI
- O’Malley, 2021, Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: final analysis, JCO, 39, 5504, 10.1200/JCO.2021.39.15_suppl.5504 · DOI
- Lorusso, 2022, Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205, JCO, 40, 5507, 10.1200/JCO.2022.40.16_suppl.5507 · doi:10.1200/jco.2022.40.16_suppl.5507
- Schmid, 2021, JCO, 39
- Boni, 2019, SGNLVA-002: Single-arm, open label phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer, Metastatic Breast Cancer, 30
- Cheson, 2020, Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial, Lancet Haematol., 7, e808, 10.1016/S2352-3026(20)30275-1 · doi:10.1016/s2352-3026(20)30275-1
- Schmidt, 2022, Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): initial results from BEGONIA, a phase Ib/II study, Ann. Oncol., 33, S194
- Vergote, 2021, 723MO Tisotumab vedotin (TV) + carboplatin (Carbo) in first-line (1L) or + pembrolizumab (Pembro) in previously treated (2L/3L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT-Cx8/GOG-3024/innovaTV 205 study, Ann. Oncol., 32, S726, 10.1016/j.annonc.2021.08.1166 · doi:10.1016/j.annonc.2021.08.1166
- Zinzani, 2019, Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II CheckMate 436 Study, J. Clin. Oncol., 37, 3081, 10.1200/JCO.19.01492 · DOI · Paper page
- Advani, 2021, Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results, Blood, 138, 427, 10.1182/blood.2020009178 · doi:10.1182/blood.2020009178
- Skinner, 2017, Integrative analysis identifies a novel AXL-PI3 kinase-PD-L1 signaling axis associated with radiation resistance in head and neck cancer, Clin. Cancer Res., 23, 2713, 10.1158/1078-0432.CCR-16-2586 · DOI
- Engelsen, 2022, Dissecting the role of AXL in cancer immune escape and resistance to immune checkpoint inhibition, Front. Immunol., 13, 10.3389/fimmu.2022.869676 · DOI
- Terry, 2019, AXL targeting overcomes human lung cancer cell resistance to NK- and CTL-mediated cytotoxicity, Cancer Immunol. Res., 7, 1789, 10.1158/2326-6066.CIR-18-0903 · DOI
- Hutchings, 2021, Glofitamab (Glofit) in combination with polatuzumab vedotin (pola): phase Ib/II preliminary data support manageable safety and encouraging efficacy in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), Blood, 138, 525, 10.1182/blood-2021-148359 · DOI
- Morschhauser, 2019, Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS), Lancet Haematol., 6, e254, 10.1016/S2352-3026(19)30026-2 · DOI · Paper page
- Liebers, 2021, Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas, Blood Adv., 5, 2707, 10.1182/bloodadvances.2020004155 · DOI
- de Oca, 2019, The anti-BCMA antibody-drug conjugate GSK2857916 drives immunogenic cell death and immune-mediated anti-tumor responses, and in combination with an OX40 agonist potentiates in vivo activity, HemaSphere, 3, 231, 10.1097/01.HS9.0000560524.63281.bc · DOI
- Callander, 2021, DREAMM-5 study: investigating the synergetic effects of belantamab mafodotin plus inducible T-cell co-stimulator agonist (aICOS) combination therapy in patients with relapsed/refractory multiple myeloma, Blood, 138, 897, 10.1182/blood-2021-152662 · doi:10.1182/blood-2021-152662
- Shekarian, 2017, Pattern recognition receptors: immune targets to enhance cancer immunotherapy, Ann. Oncol., 28, 1756, 10.1093/annonc/mdx179 · DOI · Paper page
- Amouzegar, 2021, STING agonists as cancer therapeutics, Cancers (Basel), 13, 2695, 10.3390/cancers13112695 · DOI · Paper page
- Harrison, 2007, Pharmacokinetics of 852A, an imidazoquinoline Toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans, J. Clin. Pharmacol., 47, 962, 10.1177/0091270007303766 · DOI
- Nuhn, 2018, Nanoparticle-conjugate TLR7/8 agonist localized immunotherapy provokes safe antitumoral responses, Adv. Mater., 30, 10.1002/adma.201803397 · DOI · Paper page
- Ackerman, 2021, Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity, Nat. Cancer, 2, 18, 10.1038/s43018-020-00136-x · DOI · Paper page
- Blum, 2022, Abstract 2911: The CEA-targeted ISAC, BDC-2034, shows preclinical efficacy associated with innate immune activation, phagocytosis, and myeloid reprogramming, Cancer Res., 82, 2911, 10.1158/1538-7445.AM2022-2911 · DOI
- Kang, 2022, Abstract 5616: Tumor-targeted immune activation via a site-specific TLR7-agonist antibody-drug conjugate, Cancer Res., 82, 5616, 10.1158/1538-7445.AM2022-5616 · doi:10.1158/1538-7445.am2022-5616
- Kenkel, 2022, Abstract 4252: PD-L1-targeted ISAC combines myeloid cell activation, immune-checkpoint inhibition and ADCP to improve anti-tumor efficacy over anti-PD-L1 antibodies in preclinical models, Cancer Res., 82, 4252, 10.1158/1538-7445.AM2022-4252 · DOI
- Sharma, 2021, Preliminary results from a phase 1/2 study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors, JCO, 39, 2549, 10.1200/JCO.2021.39.15_suppl.2549 · DOI
- Rodell, 2018, TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy, Nat. Biomed. Eng., 2, 578, 10.1038/s41551-018-0236-8 · DOI · Paper page
- Fu, 2015, STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade, Sci. Transl. Med., 7, 10.1126/scitranslmed.aaa4306 · DOI · Paper page
- Sato-Kaneko, 2017, Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer, JCI Insight, 2, 93397, 10.1172/jci.insight.93397 · DOI · Paper page
- Jin, 2020, Dual mechanisms of novel CD73-targeted antibody and antibody-drug conjugate in inhibiting lung tumor growth and promoting antitumor immune-effector function, Mol. Cancer Ther., 19, 2340, 10.1158/1535-7163.MCT-20-0076 · DOI
- Lupia, 2018, CD73 regulates stemness and epithelial-mesenchymal transition in ovarian cancer-initiating cells, Stem Cell Rep., 10, 1412, 10.1016/j.stemcr.2018.02.009 · DOI
- Turcotte, 2017, CD73 promotes resistance to HER2/ErbB2 antibody therapy, Cancer Res., 77, 5652, 10.1158/0008-5472.CAN-17-0707 · DOI
- Fabre, 2020, OMTX705, a novel FAP-targeting ADC demonstrates activity in chemotherapy and pembrolizumab-resistant solid tumor models, Clin. Cancer Res., 26, 3420, 10.1158/1078-0432.CCR-19-2238 · DOI
- Zammarchi, 2020, CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity, J. Immunother. Cancer, 8, 10.1136/jitc-2020-000860 · DOI
- Williams, 2020, Patient selection strategies to maximize therapeutic index of antibody-drug conjugates: prior approaches and future directions, Mol. Cancer Ther., 19, 1770, 10.1158/1535-7163.MCT-19-0993 · DOI
- Paller, 2014, Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee, Clin. Cancer Res., 20, 4210, 10.1158/1078-0432.CCR-14-0521 · DOI
- Cai, 2014, A Bayesian dose-finding design for oncology clinical trials of combinational biological agents, J. R. Stat. Soc. Ser. C Appl. Stat., 63, 159, 10.1111/rssc.12039 · doi:10.1111/rssc.12039
- Shah, 2021, The drug-dosing conundrum in oncology - when less is more, N. Engl. J. Med., 385, 1445, 10.1056/NEJMp2109826 · DOI · Paper page
Cited by
Precision treatment in advanced hepatocellular carcinoma
Yang, X., Yang, C., Zhang, S., Geng, H., Zhu, A. X., Bernards, R., Qin, W., Fan, J., Wang, C., & Gao, Q. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.01.007 · Cited by 429
Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments
Xu, J., Ding, L., Mei, J., Hu, Y., Kong, X., Dai, S., Bu, T., Xiao, Q., & Ding, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02325-5 · Cited by 389
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Qian, L., Lin, X., Gao, X., Khan, R. U., Liao, J.-Y., Du, S., Ge, J., Zeng, S., & Yao, S. Q. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00915 · Cited by 155
Yusoh, N. A., Ahmad, H., Vallis, K. A., & Gill, M. R. (2025) · Medical Oncology · doi:10.1007/s12032-025-02812-3 · Cited by 40
“Thanks to the advances in synthetic chemistry, ADCs have been designed to comprise tumour-targeting mAbs linked to cytotoxic payloads via intricately designed chemical linkers, simultaneously enabling potent effectiveness and precise targeting, thereby expanding the therapeutic index [72].”
Metadata
- Authors
- Fuentes-Antrás, J., Genta, S., Vijenthira, A., & Siu, L. L.
- Venue
- Trends in Cancer
- Publisher
- Elsevier BV
- Published
- 2023-04
- Volume
- 9
- Issue
- 4
- Pages
- 339-354
- ISSN
- 2405-8025 (ISSN-L)
- 2405-8033
- OpenAlex
- W4319164392
- Cited by
- 201
- References
- 4
- FWCI
- 11.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- Conquer Cancer Foundation
- University of Toronto
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antibody–drug conjugates: in search of partners of choice. https://app.cochat.ai/papers/10.1016/j.trecan.2023.01.003
- The paper
- Fuentes-Antrás, J., Genta, S., Vijenthira, A., & Siu, L. L. (2023). Antibody–drug conjugates: in search of partners of choice. Trends in Cancer. https://doi.org/10.1016/j.trecan.2023.01.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.